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Abstract
Through decades of research, numerous studies have generated robust evidence about effective interventions for
tuberculosis control. Yet, the global annual decline in incidence of approximately 1 % is evidence that current
approaches and investment strategies are not sufficient. In this article, we assess recent tuberculosis research
funding and discuss two critical gaps in funding and in scientific evidence from topics that have been left off the
research priority agenda.
We first examine research and development funding goals in the 2011–2015 Global Plan to Stop Tuberculosis and
analyze disbursements to different research areas by funders worldwide in 2014. We then summarize, through a
compilation of published literature and consultation with 35 researchers across multiple disciplines in the London
School of Hygiene and Tropical Medicine TB Centre, priorities identified by the tuberculosis research community.
Finally, we compare researchers’ priority areas to the global funding agendas and activities.
Our analysis shows that, among the five key research areas defined in the 2011–2015 Global Plan - namely drugs,
basic science, vaccines, diagnostics and operational research - drug discovery and basic science on Mycobacterium
tuberculosis accounted for 60 % of the $2 billion annual funding target. None of the research areas received the
recommended level of funding. Operational research, which had the lowest target, received 66 % of its target
funding, whereas new diagnostics received only 19 %. Although many of the priority research questions
identified by researchers fell within the Global Plan categories, our analysis highlights important areas that are
not explicitly mentioned in the current plan. These priority research areas included improved understanding of
tuberculosis transmission dynamics, the role of social protection and social determinants, and health systems
and policy research.
While research priorities are increasingly important in light of the limited funding for tuberculosis, there is a risk
that we neglect important research areas and encourage the formation of research silos. To ensure that funding
priorities, researchers’ agendas and national tuberculosis control policies are better coordinated, there should be more,
and wider, dialogue between stakeholders in high tuberculosis burden countries, researchers, international policymakers
and funders.
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Background
The ancient scourge, tuberculosis, was the subject of the
world’s first randomized controlled trial reported in 1949
[1], and since then numerous studies have generated
robust evidence about effective interventions for tubercu-
losis control [2]. Although highly effective treatment regi-
mens have been around for many decades [3], in 2014,
tuberculosis killed 1.5 million people, surpassing HIV to
become the leading cause of death from an infectious
disease globally [4]. Tuberculosis evades control efforts for
numerous reasons, including the lack of timely access to
quality diagnostic and treatment services for vulnerable
populations, which has contributed to the spread of drug-
resistant tuberculosis. At the current rate of decline in
incidence – just over 1 % per annum – it will take more
than 150 years to meet the World Health Organization
(WHO) targets of reducing tuberculosis deaths by 95 %
and incidence by 90 % compared to rates in 2015 [5].
Recognizing the need for major improvements in our
progress on tuberculosis control, the Stop TB Partner-
ship’s Global Plan to End TB 2016–2020 calls for a para-
digm shift [5]. While an acknowledgement of the need
for a change in approach is promising, the tuberculosis
control community has been criticized for failing to act
effectively on the basis of existing knowledge and for
constantly looking for ‘new’ solutions. Through his ana-
lysis of responses to tuberculosis in the twentieth cen-
tury, historian Christian McMillan highlights a pattern
of ‘repetition and rediscovery’ among researchers and
policymakers, owing to a tendency to ignore lessons that
have been learnt [6], resulting in a squandering of resources
on repeatedly addressing already answered research ques-
tions. This view is echoed in a review of numerous studies
carried out by the British Medical Research Council’s tuber-
culosis units between 1946 and 1986, which made the
striking assertion: “[by the late 1980s] all of the mea-
sures necessary for successful programmes for the control
of tuberculosis had been delineated” [3]. On seeing the
renewed calls for increased funding, some researchers
have questioned whether we can justify being stewards
of substantial funding for global health “if we cannot
manage a disease as well known as tuberculosis” [7].
While the barriers to managing tuberculosis are numerous,
including its association with poverty and the generation of
drug resistance owing to inadequacies in health systems,
these challenges are well defined; the balance between
generating new knowledge and identifying strategies to im-
plement proven solutions is thus being questioned.
In order to reflect upon, and learn from, our recent
research activities and priorities, we look at the past
5 years of tuberculosis research funding and discuss
two critical gaps in funding and in knowledge owing to
essential topics being left off the research priority
agenda.
Methods
We first extracted data on the funding goals for key re-
search areas in the 2011–2015 Global Plan to Stop TB
(Global Plan). The total annual funding goal for 2014, in
US dollars, was identified in the report for individual re-
search areas according to the classification used by the
authors (drugs, basic science, vaccines, diagnostics, oper-
ational research). Data on the amount of funding actually
allocated by global funding bodies in 2014 was extracted
from the 2015 Treatment Action Group report [2], classi-
fied into the same five research areas as used by the
Global Plan. Using these data, we expressed the allocated
funding amount for each research area as a percentage of
the Global Plan funding goal to assess how much of the
funding goal was achieved for each research area. We then
followed a two-step process to qualitatively compile
priority topics identified by tuberculosis researchers. In
the first step, we obtained the full text of articles on tu-
berculosis research priorities published by numerous
groups between 2006 and 2010 [8–13]; we ensured that
articles covered a wide range of possible research areas
within tuberculosis, including childhood tuberculosis,
drug resistance, diagnostics, vaccines and HIV, as well as
papers looking more broadly across the whole spectrum
of tuberculosis control. We extracted, from text and tables
in these articles, research topics that the authors identified
as being important. We classified research topics into the
same five research areas used in the Global Plan, or into
‘others’ if they did not fit into any of the five research
areas. In the second step, we updated the list of re-
searchers’ priority topics compiled based on the literature,
with additional priority research questions identified
through an in-person consultation (short, structured, one-
to-one interviews conducted in November 2015) with 35
researchers across multiple disciplines in the London
School of Hygiene and Tropical Medicine (LSHTM) TB
Centre [14]. The interviews were conducted at the annual
TB Centre meeting under the supervision of a PhD stu-
dent at LSHTM, and were recorded with respondents’
permission. Respondents were asked to identify their top
research priorities for tuberculosis control. One of the
authors (MSK) transcribed the interviews verbatim, and
classified priority research topics identified by researchers
into one of the five Global Plan research areas or ‘others’.
Duplication between priority research topics emerging
from the literature and from analysis of interviews was re-
moved, and those classified under ‘others’ were grouped
based on recurring themes or topics. Finally, we combined
the quantitative and qualitative data into a single table
(Table 1) to compare researchers’ priority topics with the
global funding agendas and activities, highlighting key
gaps. The priority research topics that did not fit into one
of the five Global Plan research areas (identified from
analyzing common themes among topics classified as
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‘other’ in the qualitative analysis) were summarized into a
separate table (Table 2).
Results
Funding needs outlined in the Global Plan
The Global Plan to Stop TB 2006–2015 was launched in
Davos, Switzerland, at the World Economic Forum in
2006 [15]. At $56 billion, the Stop TB Partnership’s fore-
casted total cost represented a three-fold increase in an-
nual investment in tuberculosis control compared with
the first Global Plan for 2001–2005 [16]. An update was
provided for the 2011–2015 period in order to set out a
clearer plan for reaching the Millennium Development
Goals and Stop TB Partnership’s 2015 targets of halving
tuberculosis prevalence and deaths compared with 1990
levels [16].
The research and development (R&D) component of
the 2011–2015 Global Plan called for approximately $2
billion in annual funding to “revolutionize the prevention,
diagnosis and treatment of TB as the foundation for
elimination of the disease” [16]. Drug discovery and
basic science were identified as the areas requiring the
majority of investment (Table 1). With a target of $1.16
billion for 2014, these two areas accounted for 60 % of the
recommended R&D funding. Basic science, which covers
fundamental research about Mycobacterium tuberculosis
and related organisms, was included as a separate research
area in the updated plan, reflecting the fact that it under-
pins the development of all new technologies. The recom-
mended level of R&D funding for basic science was set at
$420 million per year. Similarly, operational research was
included as a distinct research area in recognition of its
essential role in ensuring uptake of new tools and efficient
implementation of existing strategies. The funding allo-
cated to operational research was, however, much lower
than all other research areas, representing only 4 % of the
2014 target at $80 million.
How much funding was available?
Research funding disbursed by public funding agencies,
philanthropic and academic organizations and industry
groups over the 2011–2015 period fell far short of the
Global Plan goals. By the end of 2014, only $2.7 billion
had been invested in tuberculosis R&D since 2011, just
over one-fourth of the $9.8 billion called for. None of
the research areas were funded at the target levels in
2014 (Table 1). Operational research met two-thirds of
its target, higher than any of the other research areas,
possibly because it had the lowest target. The greatest
discrepancy between targeted and achieved funding was
for new diagnostics, which received less than one-fifth of
the $340 million goal for 2014.
To put tuberculosis research funding levels into context,
an analysis of research investments for UK institutions
Table 1 Tuberculosis (TB) research priorities identified by researchers, funding received in 2014 and Global Plan funding targets for 2014
2014 Global Funding ($m) Priority areas identified by researchersc
Targeta Actual spendingb (% of target)
Drugs 740 243.3 (33) Develop drugs (for drug-susceptible and drug-resistant TB) with higher potency,
lower toxicity and shorter duration of treatment; new prophylactic regimens;
host direct therapies
Basic science 420 150.1 (36) Identify and validate biomarkers for monitoring decease activity,
cure, relapse and of immune protection
Vaccines 380 111.3 (29) Develop safe and effective vaccines (for adults and HIV-infected patients);
understand variability in effectiveness
Diagnostics 340 65.4 (19) Improve performance of existing tests; develop new point of care tests
(for all forms, including latent and drug-resistant TB) that are cheap,
rapid and sensitive
Operational research 80 52.8 (66) Assess strategies to optimize implementation of new tools; to improve
health worker performance, private provider engagement and integration
of TB services
a2011–2015 Global Plan Target
bTreatment Action Group 2015 Report on Tuberculosis research Funding Trends, 2005–2014: A Decade of Data
cFrom literature and consultation with LSHTM TB Centre members
Table 2 Additional research priority areas that are not explicitly
included in the Global Plan, as identified by researchers
Transmission dynamics Which individuals are responsible for most
tuberculosis transmission in high burden
communities? How effective are different
interventions in interrupting transmission?
Social determinants How do structural and socioeconomic factors
increase vulnerability to tuberculosis and how
can they be addressed cost effectively?
Health systems and
policy research
How can health systems be strengthened
to better deliver quality services to at-risk
populations (comorbidities, geographically
isolated), thereby preventing generation of
drug resistance? What measures should
be taken to engage unregulated private
healthcare providers? How do we increase
evidence-based policy setting?
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concluded that tuberculosis is underfunded in comparison
to HIV and malaria, despite causing the most mortality;
between 2011 and 2013, tuberculosis research received
only 20 % of the total $344 million funding, whereas HIV
and malaria received approximately 40 % each [17]. Simi-
larly, the Global Fund to Fight AIDS, Tuberculosis and
Malaria, a funder that mainly provides programmatic sup-
port of which a small proportion goes towards research,
allocated the lowest amount of funding to tuberculosis; in
2015, disbursements were $15.5 billion for HIV, $7.2
billion for malaria and $4.1 billion for tuberculosis [18].
How well do research agendas match with researchers’
priority areas?
Within the individual research areas in the Global Plan,
tuberculosis researchers’ priority objectives included
developing better (more potent, less toxic, shorter duration
of treatment) drugs for drug-resistant and drug-susceptible
tuberculosis, identifying biomarkers for disease progression
and immune responses, developing vaccines that are
effective in adults and HIV-infected individuals, making
accessible point of care diagnostics for all forms of tuber-
culosis and assessing strategies to optimize implementa-
tion of tuberculosis control strategies.
Additional priority research areas (not explicitly in-
cluded in the Global Plan for R&D funding at present)
were also highlighted by researchers. Improved under-
standing of tuberculosis transmission dynamics was identi-
fied as a key research need in order to plan more targeted,
effective prevention interventions. The role of social pro-
tection and social determinants in tuberculosis is another
area that researchers directed attention towards; indeed,
there is a danger that neglecting to tackle socioeconomic
determinants of tuberculosis may justify criticisms about
failing to learn lessons from the massive reduction in
tuberculosis incidence in much of Europe, which was
achieved without drugs, vaccines or technologically-
advanced diagnostics [19]. Finally, health systems and
policy research is not yet included as an independent
research area in the Global Plan. Health systems and
policy research is distinct from operational research as
the latter focuses on optimizing implementation of tuber-
culosis control tools and strategies, whereas the former is
concerned with factors influencing policymakers’ deci-
sions, integration of tuberculosis control programs within
the wider health system, and studies to inform optimal al-
location of resources for tuberculosis control. Funding of
both operational and health systems and policy research is
essential for achieving maximum impact on tuberculosis
control with limited resources, an aspect that the tuber-
culosis control community is currently struggling with.
While most researchers cited priority research ques-
tions that were linked to their own work, those working
on development of new drugs, vaccines and diagnostics
recognized the importance of research to ensure that
new tools can be accessed by tuberculosis patients in
resource limited settings.
Discussion
Funding priorities are essential for the effective alloca-
tion of limited resources and they can act as a focal
point for driving financial investment. However, it is
important to critically consider funding priorities that
are being set and who is setting them. Policymakers and
funders often prefer a biomedical approach to disease
control and pay less attention to addressing more complex
sociopolitical realities and their impact on the causal path-
ways of disease [20]. It is thus encouraging that the new
Global Plan to End TB 2016–2020 recognizes that
“medical interventions alone will not be enough to end
tuberculosis” and stresses the importance of Universal
Health Coverage and social determinants [5]. It is now
vital to ensure that the R&D component of the Global
Plan – which currently focuses on only three biomedical
components: drugs, vaccines and diagnostics – prioritizes
funding for research on health systems strengthening,
translation of research into effective policies, addressing
social determinants of tuberculosis, understanding trans-
mission hotspots and analyses which inform optimal re-
source allocation.
We must also recognize that some funding streams
may encourage researchers to restrict their activities to
discrete silos, separating applied or implementation re-
search from ‘hypothesis driven’ biomedical studies. We
should therefore ensure greater support for cross-discipline
research, which many funders are now emphasizing; for
example, to explore the influence of poverty on immune
correlates and to assess the impact of different investments
(new drugs or vaccines, versus socioeconomic improve-
ments versus Universal Health Coverage) on reductions in
tuberculosis transmission and incidence.
Finally, there has to be flexibility in funding of priority
areas identified by the research community and national
tuberculosis programs themselves, such as health systems
and policy research and studies on socioeconomic deter-
minants, allowing researchers to be proactive and not only
reactive to specific funding calls. Here, tuberculosis re-
searchers must engage with funders and global policy-
makers to ensure that the research findings inform global
tuberculosis control efforts more effectively. A pragmatic
solution would be to support the formation of national
bodies for setting research agendas, including key national
stakeholders and researchers engaged in the country,
which inform global funding priorities and play a role in
evaluating research proposals in terms of applicability
and potential impact on tuberculosis in high burden
settings. Engaging local researchers would not only
build research capacity and reduce costs from engaging
Khan et al. BMC Medicine  (2016) 14:123 Page 4 of 5
primarily international teams, but also potentially aid
dissemination and uptake of findings into policy.
Resource limitations did not allow us to expand the
scope of our interviews to include researchers and policy-
makers in high tuberculosis burden countries; such a
study would allow an important additional comparison of
research priorities in international versus national institu-
tions. Furthermore, we believe that a simple exercise in
which national tuberculosis program representatives score
the potential impact of findings from a number of recently
completed studies would be very informative, and poten-
tially surprising, for researchers and funders alike. Finally,
interviews with representatives of key funding agencies
would help to better understand why some diseases are
funded disproportionately relative to disease burden (or
potential public health impact), why narrow technology
or biomedical approaches are often prioritized and how
best to influence the research funding agenda.
Conclusions
There appears to be some disconnect between funding
priorities, researchers’ agendas and global disease control
strategies. Tuberculosis receives much less research funding
than HIV and malaria despite causing more deaths globally,
and the available funding is often channeled towards bio-
medical approaches; the 2011–2015 Global Plan recom-
mended that far more funding be allocated to basic science
and drug discovery than operational research to maximize
the impact of new tools and, although the new Global Plan
to End TB 2016–2020 highlights that biomedical inter-
ventions alone are not sufficient, the R&D component
still focuses on drugs, vaccines and diagnostics. Improved
coordination between stakeholders in high tuberculosis
burden countries, researchers, international policymakers
and funders would help to ensure that critical funding and
knowledge gaps are addressed, and existing knowledge is
acted upon more effectively.
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